Bloomberg the Company & Products

Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us


Last 9.20 GBp
Change Today 0.00 / 0.00%
Volume 3.9M
OXB On Other Exchanges
Symbol
Exchange
OTC US
Frankfurt
As of 11:35 AM 07/3/15 All times are local (Market data is delayed by at least 15 minutes).

Executive Profile*

John Dawson

Chief Executive Officer and Executive Director, Oxford BioMedica PLC
AgeTotal Calculated CompensationThis person is connected to 80 board members in 2 different organizations across 3 different industries.

See Board Relationships
55680,000 GBP
As of Fiscal Year 2014

Background*

Mr. John Dawson has been the Chief Executive Officer of Oxford BioMedica PLC since October 13, 2008. Mr. Dawson has broad experience in European commercial activities, finance, and in mergers and acquisitions in the region. He is an experienced Pharmaceutical Business Leader with extensive experience in the business development arena. Mr. Dawson served as an Acting Chief Executive Officer at Oxford BioMedica PLC, from August 28, 2008 to October 13, 2008. He served as ...

Read Full Background

Corporate Headquarters*

Windrush Court
Oxford, Oxfordshire OX4 6LT

United Kingdom

Phone: 44 1865 783000
Fax: 44 1865 783001

Board Members Memberships*

2008-Present
Chief Executive Officer and Executive Director

Education*

BS
University Of Swansea

Other Affiliations*

Annual Compensation*

Salary330,000 GBP
Bonus311,000 GBP
Total Annual Compensation641,000 GBP

Stock Options*

All Other Compensation39,000 GBP
Exercisable Options1,000,000
Unexercisable Options19,313,773
Total Number of Options20,313,773

Total Compensation*

Total Annual Cash Compensation680,000 GBP
Total Short Term Compensation641,000 GBP
Other Long Term Compensation39,000 GBP
Total Calculated Compensation680,000 GBP
*Data is at least as current as the most recent Definitive Proxy.
 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
OXB:LN 9.20 GBp 0.00

COMPETITOR COMPENSATION

NamePosition/
Company
Compensation
Sijmen de Vries M.D., MBAChief Executive Officer and Member of Management Board
Pharming Group NV
€624.0K
Clive A. Meanwell M.D., Ph.D.Chairman and Chief Executive Officer
The Medicines Company
$874.6K
Cameron Geoffrey McDonough M.D.Chief Executive Officer and President
Swedish Orphan Biovitrum AB
kr5.4M
Edwin Moses Ph.D.Chief Executive Officer, Director and Member of Research & Development Committee
Ablynx NV
--
William J. Polvino M.D.Chief Executive Officer and President
Veloxis Pharmaceuticals A/S
--
Compensation as of Fiscal Year 2014.

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact OXFORD BIOMEDICA PLC, please visit . Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.